Isolation of pulmonary veins using a thermoreactive implantable device with external energy transfer : evaluation in a porcine model by Boussy, Tim et al.
Received: 14 November 2017 Revised: 2March 2018 Accepted: 26March 2018
DOI: 10.1111/pace.13345
D EV I C E S
Isolation of pulmonary veins using a thermoreactive
implantable device with external energy transfer: Evaluation in
a porcinemodel
Tim BoussyMD1 TimVandecasteele DVM2 Lisse Vera DVM3
Stijn Schauvliege DVM, PhD4 Matthew Philpott IR5 Eli Clement IR5 Gunther van
LoonDVM, Phd3 UdiWillenz DVM6 Juan F. GranadaMD7 GreggW. StoneMD8
Vivek Y. ReddyMD9 Glenn Van LangenhoveMD, PhD5
1Department of Cardiology, AZGroeninge
Kortrijk/AZMMiddelares, Ghent, Belgium
2Department ofMorphology, Faculty of Vet-
erinaryMedicine, GhentUniversity, Ghent,
Belgium
3Department of LargeAnimal InternalMedicine,
Faculty of VeterinaryMedicine, GhentUniver-
sity, Ghent, Belgium
4Department of Surgery andAnesthesia of
Domestic Animals, GhentUniversity, Ghent,
Belgium
5FulgurMedical,Merelbeke, Belgium
6LahavCRO, Laboratory of Preclinical Services,
Kibbutz Lahav, Israel
7CRF-Skirball Center for Innovation,Orange-
burg, NY, USA
8Cardiovascular Research Foundation, Columbia
University, NewYork, NY, USA
9Helmsley ElectrophysiologyCenter, Icahn
School ofMedicine atMount Sinai, NewYork,
USA
Correspondence
TimVandecasteele,DepartmentofMorphology,
FacultyofVeterinaryMedicine,University
Ghent, Salisburylaan133, 9820Merelbeke,
Belgium.
Email: Tim.Vandecasteele@Ugent.be
SourcesofFunding:None.
Disclosures:G.VanLangenhove is founderof
the companyFulgurmedical andhasequity. E.
Clement andM.Phillpott bothareemployeesof
FulgurMedical, the company thatdeveloped the
implant, the applicator, and thedelivery system.
Abstract
Background: Pulmonary vein isolation (PVI) is a well-established method for the treatment of
symptomatic paroxysmal atrial fibrillation, but is only partly successful with a high rate of elec-
trical reconnection. We introduce a novel technique in which PVI is accomplished by noninvasive
heating of a dedicated thermoresponse implant inserted into the pulmonary veins (PV), demon-
strated in a porcinemodel.
Methods: A self-expanding nitinol-based implant was positioned in the common inferior PV of
11 pigs, using a fluoroscopy-guided transatrial appendage approach. Ablation was performed
through contactless energy transfer from a primary extracorporal coil to a secondary heat ring
(HR) embedded in the proximal part of the implant. Electrophysiological conduction was assessed
prior to andpostablation, and at 3months.Histological sampleswere obtained acutely (n = 4) and
after 3months (n = 7).
Results: In total, 13 PV implants were successfully positioned in the inferior PVs of 11 animals.
Ablation was performed without injury of adjacent structures. PVI and bidirectional block was
electrophysiologically confirmed in all cases immediately at the timeof implantation and3months
later in seven chronic animals in whom testing was repeated.Marked evidence of ablation around
the proximal HRwas evident at 3months postprocedure, with scar tissue formation and onlymild
neointimal proliferation.
Conclusions: Successful PVI can be obtained by external electromagnetic heat transfer to a novel
pulmonary vein implant.
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1 INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia in human
adults. The overall prevalence of AF is estimated between 1.5% and
2% of the general population.1 Furthermore, since AF can also be
asymptomatic, the true prevalence of this disease is likely to be
underestimated. Because AF is associated with a fivefold increased
risk of stroke and a threefold increased incidence of heart failure, the
impact of AF on patient well-being and societal health care expendi-
tures is enormous.2,3 In the last two decades, pulmonary vein isolation
(PVI) has become the preferred treatment of patients with paroxysmal
atrial fibrillation. Current PVI techniques show 1-year success rates of
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64–70%. Success rates appear to be even lower when analyzing long-
term results (44–54%).1–4 In this article, we introduce a novel nonin-
vasive ablation technique using electromagnetic energy transfer from
an extracorporal coil to a self-expanding, heatable device permanently
positioned inside the PVs.
2 METHODS
2.1 Implant
Wedeveloped a self-expanding nitinol-based implant that ensures per-
manent fully circumferential contact with the PV wall. Three differ-
ent regions are distinguishable: the active heating section or heat ring
(HR), the connection part, and the stabilizing support part (Figure 1).
As described below, the implant was placed into the proximal segment
of the PV via a fluoroscopy-guided transatrial approach.
2.2 Principles of electromagnetic energy transfer
(inductive power transmission)
The heating of the implant (and consequently tissue ablation) in the
PVs is achieved through contactless transfer of energy from a primary
transmitter coil (L1 in Figure 1) to a secondary receiver coil (L2 in
Figure 1). The energy delivered to the primary coil originates from
a 400-V three-phase mains supply. This supply is transformed by the
converter (Easyheat 8310 LI, Ambrell, Scottsville, NY, USA) through
the primary coil to generate the required electromagnetic field, which
induces a current in the secondary coil. This current then, dependingon
the electrical properties of the coil material, results in heating of the
secondary coil (the implant). Using the converter, the amount of elec-
tromagnetic energy generated can be adjusted. The coupling factor
(the energy transfer efficiency between coils) is approximately 2.1% at
an operating frequency of 370 kHz. The coupling factor decreaseswith
the cosine (cos) of the angle between the transmitter and receiver coil.
Figure 1 shows the custom-made primary coil.
2.3 Noninvasive temperature-controlled ablation
As the extent of thermal injury is dependent upon the uniformity of
contact between theHRandPV tissue, the local temperature achieved,
and duration of the ablation, we assessed the temperature achieved
through temperature sensors located between the HR and the venous
tissue (which approximates the actual vein tissue surface temper-
ature). We used the Opsens OTG-M170 fiberoptic sensor (Opsens,
Quebec City, Canada) for temperature measurement. A two-lumen
concept was utilized with the temperature sensor able to be freely
repositioned to localize the optimal position for temperature feedback
(Figure 1). When activating the electromagnet, using a test dose, small
temperature increases were sought to determine the optimal position
of the temperature sensor with respect to the implant. Using Comsol
simulations, we calculated the temperature profile along an axial line
between the implant and tissue.
2.4 Animal model
The porcine model was used for catheterization of the PVs. The breed
chosenwas amixture between Land race and Largewhite, and the ani-
mals were between 3 and 4 months of age, weighing between 60 and
65 kg. This age and size of the pigs was chosen so that they would
fit inside the transmitter coil with an inner diameter of 30 cm. Eleven
animals were used. All animals were orally preloaded with oral aspirin
300 mg and clopidogrel 300 mg at least 24 hours preprocedure, and
were continued on aspirin 75mg and clopidogrel 75 mg daily until ter-
mination of the trial.
2.5 Procedure
2.5.1 Experimental setting
Under general anesthesia, a left thoracic incision in lateral positionwas
made and direct puncture of the left atrial appendage was performed.
A sheath was placed over a guidewire. A second guidewire was placed
through the sheath. The sheathwas takenout of the left atriumandput
in place again, but only over one of the two guidewires, thus provid-
ing direct sheath access to the left atrium (for placement of the tem-
perature control system) and a guidewire for delivery of the implant.
A guiding catheter was brought into the left atrium, and contrast dye
was injected to visualize the antrum and PV ostia. Both guidewires
were positioned distally into the common inferior vein. These images
were stored and used as a guide. The outline of the PVs was drawn
on the monitor, also as a guide. The PV diameter was then measured
angiographically using avalidatedonlinequantitative system (Siemens,
Munich, Germany), and the appropriate size of the implantwas chosen.
Implants were chosen to be ≥10% larger in diameter than the angio-
graphic measurement.
2.5.2 Implant positioning
The implant was introduced into the PV and positioned at the atri-
opulmonary junction, specifically in the antrum of the PV ostium (at
the transition between the ostium and left atrium, and the nonmus-
cular parts of the PV). Positioning and deploying of the implant was
performed using angiography. After the implantation of the device, the
transmitter coilwas positioned in exactly the sameplane as the heating
segment of the implant.
2.5.3 Noninvasive ablation
Correct temperature probe positioning was performed using an abla-
tion test dose.When the correct position was confirmed, the tempera-
ture probe was fixed, and the calculated ablation power was delivered
over 3 minutes. The power needed was calculated using a proprietary
algorithm, which incorporates the size of the implant, the measured
expansion, and the calculated deviation from the perfect alignment of
device and ablation coil in the same plane. The temperature probe was
removed after 2 minutes, to also ensure ablation of the small space
where the temperature probewas positionedbetween the implant and
the PVwall.
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F IGURE 1 Panel 1: Schematic drawing of an inductive coupled power transfer system. L1 is the primary (transmitter) coil with diameter D, L2
is the secondary (receiver) coil with diameter D2. The efficiency of the power transfer depends on the coupling (k) between the coils and their
quality (Q). The coupling is determined by the distance between the transmitter and receiver coil (z) and the ratio of D2 /D. The coupling is further
determined by the shape of the coils, the angle between them, and the used frequency. Panel 2: The custom-made coil (Verhaert NV, Kruibeke,
Belgium). The coil has two water-cooled copper windings that are electrically insulated. Panel 3: X-ray image of the implant with delivery catheter
(A), guidewire (B), heating segmentwith diamond-like struts that create resistancewhich allow current to be transformed into heat (C), connecting
segment (D), and stabilizing support structure (E). Panel 4: Schematic figure of the temperature probe
2.5.4 Verification
After the ablation, the position of the implant was again checked using
angiography, to ensure the device had remained in the same position.
Prior to and following the ablation, a 10-pole steerable diagnostic elec-
trophysiologic (EP) catheter (Viacath, Biotronik, Berlin, Germany) was
introduced into the PVs. Distal pacing was performed to check for exit
block.
After removal of all catheters, four animals were sacrificed imme-
diately, and seven at 3 months. The animals that survived were again
catheterized at 3 months, and conduction block patency checked.
Heart and lungs were carefully inspected macroscopically, and speci-
mens of the PVswere histologically evaluated.
3 RESULTS
3.1 Animal characteristics
In total, 11 pigs were treated. In all animals, the antrum of the inferior
PVwas chosen as the ablation target. Nomajor periprocedural compli-
cations occurred. A single implant was placed in 10 animals while two
implants were placed in one animal. The sequence of the two implants
being placed into the two PVs (i.e., left and right) from upper left to
lower right is shown in Figure 2.
3.2 Implants
Figure 2 shows an example of angiographic measurements prior to the
implantation. Table 1 shows the procedural data. All implantswere suc-
cessfully positioned. In pig number 7, two implants in two different PVs
were implanted. In pig number 11, one implant dislocated from the PV
due to undersizing of the device, which embolized to the left atrium.
Therefore, this animal was sacrificed immediately. Average duration
of the procedure was 81 ± 22 minutes including surgery, catheteriza-
tion, implant delivery, and ablation. The implantation and ablation pro-
cess took 17 ± 6 minutes. After device implantation, the ablation coil
was positioned over the animals. The coil was positioned such that the
ablation coil and the implant were in the same plane. Deviations of the
plane were fed into the algorithm described above and power/current
delivered was adjusted accordingly. Temperature measurements were
performed following a fixed protocol. Table 2 shows the current pro-
vided to the ablation coil and the temperatures reached during the
procedures. The average temperature increase generated in the vessel
wall was 8.9± 6.8 ◦C. Duration of ablation was 200± 201 seconds.
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F IGURE 2 Panel 1: Implantation sequence with two consecutive implants being placed into both pulmonary veins ostia (left and right) from
upper left to lower right. Panel 2: Angiographic measurements of the antrum of the inferior pulmonary vein complex. (A) The reference measure-
ment taken with the injection sheath (7 French) taken as actual reference. (B) The actual measurements and (C) the corresponding sites where the
measurements were taken [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Procedural data of the 11 treated pigs
Pig number Age (months) Size (kg)
Common PV
size (diameter,
mm)
Implant size
(mm)
Successful
placement of
implant
Total
procedural
time (min)
1 3 60 14 25 Yes 80
2 3 62 18 25 Yes 75
3 3 60 21 30 Yes 55
4 3 65 27 30 Yes 90
5 3 63 22 25 Yes 80
6 3 61 23 25 Yes 60
7 (*) 3 65 14 25 Yes 115
15 25 Yes
8 3 62 21 25 Yes 85
9 3 63 13 25 Yes 125
10 3 63 22 25 Yes 70
11 (**) 3 61 23.5 (average
of 20 (distal)
and 27
(proximal))
30 Yes (**) 60
Note: *In pig number 7, two implants were positioned into two different pulmonary veins.
**First implant in this animal dislocated from the PV into the left atrium. PV= pulmonary vein.
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TABLE 2 Temperature and data during testing and ablation
Pig number
Core body
temperature
(◦C) VWT pre (◦C)
Positioning
test dose
current (amp)
VWTPeak
(◦C) 횫 ◦C
Max Current
(amp)
Duration of
ablation (sec)
1 33.4 39.0 148.8 58 25.6 284 180
2 33.8 None 150.4 40 6.2 302.4 180
3 34.3 35.7 165.9 40 5.7 275.1 180
4 33.5 35.2 243.6 38 4.5 390.0 180
5 35.9 Dislocated
temp sensor
NA NA 396.0 180
6 35.1 36.0 207.9 39.0 3.9 401.1 180
7 35.1 36.5 310.8 40.0 4.9 399.0 180
35.1 36.0 310.8 37.0 1.9 399.0 180
8 35.5 35.8 140.8 49 13.5 300.8 300
9 36.0 42.0 201.6 49 13.0 270.4 300
10 35.4 39.0 150.4 52 13.0 284.0 180
11 33.7 35.0 133.3 40 6.3 354.1 180
Note: Core body temperature = anal measurement of pig body temperature. VWT pre = vessel wall temperature prior to ablation; VWT-peak = peak tem-
perature during ablation;Δ◦C= Temperature increase.
TABLE 3 Results of sensing and pacing from a distal focus in the
pulmonaryveinbefore andafter implantationandheatingof thedevice
Pig
number
Signals
recorded
preablation
Conduction
of paced
signals
preablation
Conduction of
paced signals
postablation
Long-term
persistence of
conduction
block (3
months)
1 + + – +
2 + + – +
3 + + – +
4 + + – +
5 + + – +
6 + + – +
7 + + – +
+ + – +
8 + + NA NA
9 + + NA NA
10 + + NA NA
11 + + NA NA
3.3 Electrophysiological testing
Prior to ablation, PV signals were detected distally from the HR in
all animals, demonstrating intact conduction. After ablation, the same
location was checked for entry and exit block. Bidirectional block was
confirmed from the 11 tested PVs in 10 animals. EP characteristics are
shown in Table 3.
3.4 Acute tissue injury evaluation
Four animals were sacrificed immediately, and seven were kept alive
for 3 months. In the animals that were sacrificed immediately, the
ablation zone was evaluated after removal of the implants for gross
anatomical changes. A typical ablation zone is shown in Figure 3. No
damage to the surrounding structures was observed in any of the four
acute animals, nor in the seven chronic ones.
3.5 Histology
Histological data of the seven animals at 3 months postprocedure
showedmarked evidence of ablation around the proximal HRwith loss
of tissue architecture and scar tissue formation. There was no inflam-
mationor necrosis adjacent to themid anddistal sectionof the implant.
A mild degree (0.4 ± 0.7 mm) of neointimal proliferation was noted
(Figure 3). Figure 3 demonstrates the Mallory-Azan-stained ablated
myocardial sleeve tissue, in which ingrown fibrous connective tissue,
due to the ablation procedure, is indicated by blue staining.
4 DISCUSSION
In this report, we have shown for the first time that complete PVI using
an externally applied energy source is safe and feasible via a novel
catheter-delivered implant. In this experiment, 11 animals received
nitinol self-expanding implants into the antrum of the inferior PV
without periprocedural complications. In all animals, the current test
allowedestablishing anoptimal temperature-sensing zone, afterwhich
a full ablation currentwas applied. All treatedPVswere electrically iso-
lated without vascular necrosis or other evidence of damage to adja-
cent structures. No PV electrical reconnections occurred 3 months
postablation in seven studied animals.
4.1 Ablation target
In contrast to current ablation modalities, this new approach targets
the PVs via a permanent implant. PVI is achieved by uniform heating of
the implant's proximal ring. Preliminary histological results show only
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F IGURE 3 Panel 1: View from the left atrium after sacrifice of the animal. (A) The left atrium with the antrum of and entrance to the inferior
pulmonary vein. (B) The pulmonary vein implant in situ. Panel 2: Left atrium opened from the anterior side. Mitral valve (A); left atrium (B); original
position of the implant with the diamond-shaped struts of the ablation ring (C); ablation zone in the pulmonary vein revealing the same diamond-
like shape (D); and distal side of the pulmonary vein (E). Panel 3: Imprint of the implant after ablation and removal of the implant. A continuous
circumferential ablation zone in the transition zone between pulmonary vein and left atrium is seen. The diamond-like shape of the ablation zone is
clearly visible. Panel 4: Detailed section of the ablated pulmonary vein of pig number 2. Clear demarcation of the ablation effect of a single strut of
the implant is visualized by white arrows. Panel 5: Representative histologic images at 3 months. (A) Histological samples alongside the proximal,
mid, and distal regions of the implant. (B) Pulmonary vein, proximal section showing loss of tissue architecture. (C) Pulmonary vein, mid section,
revealing no inflammation or necrosis andmild neointimal formation. (D) Pulmonary vein, distal section, without inflammation or necrosis andmild
neointimal formation. Panel 6: Histologic image of myocardial sleeve tissue of the inferior PV. Ingrown fibrous connective tissue (stained blue) was
present as reaction on the ablation procedure, myocardial tissue is stained orange to red. Top side is the lumen, Mallory-Azan staining, scale bar is
500 𝜇m [Color figure can be viewed at wileyonlinelibrary.com]
minimal intimal proliferation, suggesting that PV stenosis as a poten-
tial complication may be infrequent.5,6 As a result of expansion of the
vein during implant deployment, a slight increase in PV size was seen,
despite scar formation on the HR 3months postablation.
Precise positioning of the HR potentially enables exact ostial iso-
lation of the PVs in a safe manner. Current (antral) ablation tech-
niques are often challenged by considerable differences in tissue thick-
ness (posterior wall vs left atrial appendage ridge).7 If the perivenous
myocardial tissue around the PVs itself can be targeted, application of
a short uniform circumferential heating protocol should be sufficient
to achieve PVI, as observed herein.
4.2 Potential advantage of a permanent implant
Currently, AF recurrence following PVI is thought to be mainly due to
gap formation in the ablation zones or tissue recovery.8 Contributing
factors are both patient related (PV anatomy, individual scar forma-
tion) and technique related (radiofrequency vs cryoablation, operator
skill, etc.).9 In the present study, we sought to evaluate the PV recon-
nection rate in the presence of permanent implants, positioned slightly
more to the ostial side of the traditional RF ablation zone. Theoreti-
cally, the chronic presence of the devicewould facilitate repeated elec-
tromagnetic heating should AF recur.
4.3 Externally delivered ablative energy
For the first time, we have demonstrated a method wherein the
energy required for ablation is delivered from an external source to
an indwelling implant, in contrast to current clinical strategies where
radiofrequency or cryoablative energy is delivered locally from an
indwelling catheter. The potential advantages of this new technique
aremultiple and include:
1. The amount of energy delivered can be tailored individually,
depending on patient characteristics, size, and orientation of the
implants.
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2. The adjustment and calculation of the magnetic field results in
focused heating of the implant without damaging surrounding
structures.
3. A short ablation time (±200 seconds) is needed for effective lesion
formation.
4. Ablation may be performed offline. In case of recurrence, repeat
ablation could be performed in an ambulatory setting.
5. Since the ablation target is located more distally in comparison to
conventional techniques, formation of atrioesophageal fistulas is
less likely to occur.10
4.4 Limitations
This article describes the feasibility of a new techniquewith the poten-
tial to disrupt the way PVI procedures are performed. Especially the
potential to simplify the procedureminimizing theuseof complexmap-
ping and ablation techniques are appealing. However, there are several
limitations that deserve to be highlighted:
1. Separate energy delivery is needed for each implant, since setting
of the magnetic field and positioning of the external coil need to be
adjusted to each implant's position and orientation. This could be
completed in one procedure, however, as each ablation session is
short.
2. Although the ablation itself is not invasive, positioning of multiple
devices is. Nevertheless, shorter procedure times are possible than
for current techniques.
3. This techniquemay not be sufficient for patients with persistent or
long-standing persistent AF, since the underlying mechanism of AF
may not be confined to the PVs.11
4. Although all seven chronic animals were in apparent good health
before sacrifice, we did not actively investigate the possibility of
phrenic nerve injury.
5. AF ablation is not limited to PVI but this poses a limitation for this
technology as no additional ablation lines can be applied with this
technique.
6. In our study, we cannot conclude whether the stent implantation
or ablation procedure was associated with thrombus formation.
Therefore, prior to human trial initiation, further investigations
using brain magnetic resonance imaging are needed to assess the
risk of thromboembolization and potential brain injury.
4.5 Future developments
Several improvements in this technology are under investigation and
need to be implemented in future studies. First, in this study, the PVs
were approached through the transatrial approach. Thiswill need tobe
adapted to a transseptal approach.12 Second, we implanted one single
device per animal, while in humans up to four implants will be needed
to achieve full PVI. However, in contrast to arterial stents that con-
tain a considerable amount ofmetal to achieve sufficient radial support
(and provoke substantial vascular responses), the present implants
target expansion of venous structures. Therefore, these implants imply
amuch lowermetallic burdenand radial force andneointimal hyperpla-
sia has beenminimal.
In our experiment, the temperature sensor was placed adjacent to
the implant, andwas removed during the procedure. This may prove to
be impractical when implants need to be placed into several PVs dur-
ing the same procedure (as the temperature probe needs to be posi-
tioned through a separate guiding catheter for each PV). Other means
for assessing the amount of energy delivered locally to the implant
(and the temperature generated) are currently being developed. Flexi-
ble microelectronics could be added to the implant, allowing real-time
in situ temperature feedback during ablation, electrical signal recogni-
tion, and even detection and monitoring of acute and chronic intrac-
ardiac electrocardiographic signals (to derive a 12-lead electrocardio-
gram), to monitor for AF recurrence, etc. Position and orientation of
the implant with respect to the transmitter coil is of high importance.
Currently, it is difficult to find the optimal position of the transmit-
ter coil for efficient and homogenous heating of the implant. Three-
dimensional (3D) mapping or other visualization techniques should
improve or overcome this limitation.
The entire procedure took on average 81 minutes, including posi-
tioning of the ablation coil around the animal, which proved cumber-
some and often required 30–40 minutes. Significantly shorter proce-
dure times are expected in the future. However, complete electrical
isolation would require an implant in each PV. In our study, conduction
block acutely and at 3 months was demonstrated via pacing on both
sides of the ablation ring. Long-term validation is needed using a 3D
electromagnetic mapping system to confirm a closed circumferential
ablation line as well as bidirectional block.
5 CONCLUSIONS
In the present study, we have demonstrated that implantation of a self-
expanding nitinol-based device in the PVs is safe and feasible, and that
energy can be delivered to the implant in a noninvasive, controlled
manner, achieving bidirectional conduction block without complica-
tion. Compared to contemporary techniques to achieve AF ablation,
this device may provide advantages including ease of use, consistency
of effect, and repeatability, if necessary. Further device iterations and
techniquemodifications are ongoing to improve the utility of this novel
approach.
ORCID
Tim Vandecasteele DVM http://orcid.org/0000-0002-0710-3702
REFERENCES
1. Camm AJ, Lip GY, De Caterina R, et al. Focused update of the ESC
guidelines for the management of atrial fibrillation: an update of the
2010 ESC guidelines for the management of atrial fibrillation. Devel-
oped with the special contribution of the European Heart Rhythm
Association. Eur Heart J. 2012;33:2719–2747.
8 BOUSSY ET AL.
2. Healey JS, Connolly SJ, GoldMR, et al. ASSERT Investigators. Subclini-
cal atrial fibrillation and the risk of stroke.NEngl JMed.2012;366:120–
129.
3. Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and
outcomes in patients with atrial fibrillation and heart failure: the
Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012;14:295–
301.
4. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of
catheter ablation of atrial fibrillation: a systematic review and meta-
analysis. J Am Heart Assoc. 2013;2:e004549. https://doi.org/10.1161/
JAHA.112.004549.
5. Lu HW, Wei P, Jiang S, et al. Pulmonary vein stenosis compli-
cating radiofrequency catheter ablation: five case reports and lit-
erature review. Medicine. 2015;94:e1346. https://doi.org/10.1097/
MD.0000000000001346.
6. Dill T, Neumann T, Ekinci O, et al. Pulmonary vein diameter reduction
after radiofrequency catheter ablation for paroxysmal atrial fibrilla-
tion evaluated by contrast-enhanced three-dimensional magnetic res-
onance imaging. Circulation. 2003;107:845–850.
7. McLellan AJ, Ling LH, Azzopardi S, et al. A minimal or maximal abla-
tion strategy to achieve pulmonary vein isolation for paroxysmal atrial
fibrillation: a prospectivemulti-centre randomized controlled trial (the
Minimax study). Eur Heart J. 2015;36:1812–1821.
8. Santangeli P, Lin D. Catheter ablation of paroxysmal atrial fibrilla-
tion: have we achieved cure with pulmonary vein isolation?Methodist
Debakey Cardiovasc J. 2015;11:71–75.
9. Kuck KH, Hoffmann BA, Ernst S, et al. Gap-AF–AFNET 1 Investigators.
Impact of complete versus incomplete circumferential lines around
the pulmonary veins during catheter ablation of paroxysmal atrial
fibrillation: results from the Gap-Atrial Fibrillation-German Atrial
Fibrillation Competence Network 1 Trial. Circ Arrhythm Electrophysiol.
2016;9:e003337. https://doi.org/10.1161/CIRCEP.115.003337.
10. Chavez P, Messerli FH, Casso Dominguez A, et al. Atrioesophageal
fistula following ablation procedures for atrial fibrillation: systematic
review of case reports. Open Heart. 2015;2:e000257. https://doi.org/
10.1136/openhrt-2015-000257.
11. Climent AM, Guillem MS, Atienza F, Fernández-Avilés F. Electro-
physiological characteristics of permanent atrial fibrillation: insights
from research models of cardiac remodeling. Rev Cardiovasc Ther.
2015;13:1–3.
12. Bollmann A, Kosiuk J, Hilbert S, John S, Hindricks G. Percutaneous
transapical access for pulmonary vein mapping and ablation in a
porcine model with a new high-density electroanatomical mapping
system. Int J Clin ExpMed. 2015;8:12631–12636.
How to cite this article: Boussy T, Vandecasteele T, Vera
L, et al. Isolation of pulmonary veins using a thermoreac-
tive implantable device with external energy transfer: Evalu-
ation in a porcine model. Pacing Clin Electrophysiol. 2018;1–8.
https://doi.org/10.1111/pace.13345
